Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat.
The induction of endogenous vascular endothelial growth factor (VEGF) production in the skin flap with ischemic injury and the effect of exogenous VEGF on survival of the ischemic skin flap were studied in rats. A dorsal flap model (3x10 cm(2)) was used in this study. In Part I, biopsies were taken from the flap at 2.5, 5.5, and 8.5 cm distances from the distal edge at 0, 6, 12, and 24 h after the flaps were sutured. Malonyldialdehyde (MDA) and VEGF(165) protein level were measured. In Part II, exogenous VEGF (1 microg/ml) was injected subdermally into the flaps in 14 rats before the flaps were replaced. Flaps that received a saline injection were used as the controls. The skin paddle survival was measured on postoperative day five. The results showed that the MDA level in the distal part of the flap significantly increased at 24 h postoperatively when compared to MDA in other parts of the flap. However, VEGF levels in the distal part of the flap significantly decreased when compared to the middle part of the flap. Subdermal injection of exogenous VEGF to the distal area of the flap could significantly improve survival of the distal flap (89% of total skin paddle) when compared to the control, which had a 64% mean percent survival. We conclude that production of endogenous VEGF protein is significantly increased in the skin flap with mild ischemia, but decreased in the flap with severe ischemia. Administration of exogenous VEGF could significantly enhance survival of ischemic flaps.
Zhang
F
F
Division of Plastic Surgery, The University of Mississippi Medical Center, Jackson, MS 39216, USA.
Oswald
T
T
Lin
S
S
Cai
Z
Z
Lei
M
M
Jones
M
M
Angel
M F
MF
Lineaweaver
W C
WC
D000818:Animals; D016228:Endothelial Growth Factors / Q000032:analysis* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006085:Graft Survival / Q000187:drug effects* / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis* / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy; D015227:Lipid Peroxidation; D008222:Lymphokines / Q000032:analysis* / Q000627:therapeutic use; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D012867:Skin / Q000098:blood supply / Q000378:metabolism; D013524:Surgical Flaps / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008315:Malondialdehyde